• Punctal Plug Delivery System

Sustained Drug Delivery for Ophthalmology

• Bob Butchofsky, CEO, Mati Therapeutics Inc.

BButchofsky@MatiTherapeutics.com
CMuller@MatiTherapeutics.com
Evolute® Punctal Plug Delivery System

Consistent efficacy and therapy control delivered easily and comfortably
Excellent Plug Retention Rates Over 12 Weeks

U.S. Phase II Multi-center Trials

<table>
<thead>
<tr>
<th>Study</th>
<th>Week 4</th>
<th>Week 8</th>
<th>Week 12</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glau 12 (n = 92)</td>
<td>98%</td>
<td>97%</td>
<td>96%</td>
</tr>
<tr>
<td>Glau 13 (n = 87)</td>
<td>98%</td>
<td>96%</td>
<td>92%</td>
</tr>
</tbody>
</table>
### Multiple Disease State Treatment Applications

#### Multiple compounds can be formulated with Evolute® Punctal Plug Delivery System

<table>
<thead>
<tr>
<th>Glaucoma</th>
<th>Allergy</th>
<th>Anti-Inflammatory</th>
<th>Dry Eye</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prostaglandins</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Latanoprost ▲</td>
<td>Antihistamines / Mast Cell Stabilizers</td>
<td>Steroids</td>
<td></td>
</tr>
<tr>
<td>• Travoprost ▲</td>
<td>• Olopatadine ▲</td>
<td>• Difluprednate ▲</td>
<td></td>
</tr>
<tr>
<td>• Bimatoprost</td>
<td>• Levocabastine</td>
<td>• Dexamethasone ▲</td>
<td></td>
</tr>
<tr>
<td>Beta-Blockers</td>
<td>alcaftadine</td>
<td>• Loteprednol</td>
<td></td>
</tr>
<tr>
<td>• Timolol</td>
<td>Mast Cell Stabilizers</td>
<td>• Fluorometholone</td>
<td></td>
</tr>
<tr>
<td>• Betaxolol</td>
<td>• Cromolyn</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Levobunolol</td>
<td>• Nedocromil</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alpha Agonists</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Brimonidine</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCEs</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Rho Kinase Inhibitors</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Adenosine agonists</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Additional Information

*OTC Demulcents / Oils / Emulsions*
Mati Therapeutics Inc. N-Evolute® Phase II Trial

• Study Design
  • Double masked
  • Placebo controlled
    • Nepafenac Evolute® Vs Placebo Evolute®
  • Randomized 2 to 1 in favor of active
  • Post Operative Cataract Trial
  • End Points = Pain and Inflammation
  • Plugs Inserted 1-2 Days Pre-Op
  • N for interim analysis = 44 (29 N-Evolute® – 15 Placebo)
• Balanced Baseline Demographics & Surgical Procedure
  • Age, Gender, Race
  • Cataract Grade, Incision Size, Ease of Cortex Removal
• Plug Retention:
  • After 212 Total Patient Visits Over 2 Weeks of Follow Up – one plug (N-Evolute®) was not present and positioned normally
Nepafenac Evolute® Phase II Results

Percent of Patients with **No Pain**
Day 3 Post Op

- **N-Evolute**: 66%
- **Placebo Evolute**: 25%

Day 3 Post Op

% of patients

N-Evolute
Placebo Evolute
Nepafenac Evolute® Phase II Results

Percent of Patients with **No Pain** Throughout Entire Trial Period

- **43%** of patients with no pain
- **0%** of patients in the placebo group
Nepafenac Evolute® Phase II Results

Percent of Patients with None or Trace Pain
Day 3 Post Op

- **N-Evolute**: 76%
- **Placebo Evolute**: 42%

Day 3 post op

% of patients
Nepafenac Evolute® Phase II Results

Percent of Patients with None or Trace Anterior Chamber Cells
Day 3 Post Op

- 86% for N-Evolute
- 50% for Placebo Evolute
Nepafenac Evolute® Phase II Results

Percent of Patients with None or Trace Anterior Chamber Flare

Day 3 Post Op

- **N-Evolute**: 95%
- **Placebo Evolute**: 67%

% of patients
Amfenac is the active form of Nepafenac. Initial formulation achieved a concentration greater than 10x the IC50 for COX2 inhibition. New formulation will exceed these high levels.

*Approximation
Nepafenac Evolute® Phase II Results

Percent of Patients with Uncorrected VA 20/50 or Better
Day 3 and Day 7 Post Op

Day 3 Post Op
- N-Evolute: 71%
- Placebo Evolute: 50%

Day 7 Post Op
- N-Evolute: 83%
- Placebo Evolute: 50%
Mati Therapeutics Inc. N-Evolute® Phase II Trial

• Adverse Events
  • Total of 11 Adverse Events Reported:
    • 7 N-Evolute® (24%)
    • 4 Placebo (27%)
  • No Serious AEs
  • No Unexpected AEs
Key Development Activity over the Next 12 Months

- Complete Nepafenac Phase II Trial
- Travoprost POC Trial in OH and Glaucoma
- Steroid – Post cataract inflammation and Pain Phase II Study
- Complete Cyclosporine Formulation Activity
- Prepare for Phase III Trial for Nepafenac in 2019

<table>
<thead>
<tr>
<th>Activity</th>
<th>Q4-2018</th>
<th>Q1-2019</th>
<th>Q2-2019</th>
<th>Q3-2019</th>
<th>Q4-2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Complete E-Nepafenac Phase II</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>E-Travoprost Trial</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>E-Steroid – Post Cataract</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Verify E-Cyclosporine Formulation</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phase III E-Nepafenac</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Strong Intellectual Property Position

112 issued patents (27 issued in 2017)
61 pending applications
17 patent families

U.S. Patent, De Juan
“Use of ocular implants to deliver a therapeutic agent to the eye, either placed through the punctum or between the sclera and conjunctiva tissue layer.”
Evolute® Punctal Plug Delivery System

• Summary Of Benefits
  • Wide range of compounds
  • Flexible drug delivery profile
  • Non-invasive approach
  • Steady elution – unlike eye drops
  • Comfortable + excellent retention
    – 92% and 96% in last two clinical trials at 12 weeks
  • Cosmetically invisible / easily identifiable
  • Preservative free
  • “Passive” system for patients / physician controls compliance
  • Favorable reimbursement opportunity for MDs and ODs
  • Strong IP protection
Evolute® Punctal Plug Delivery System

Consistent efficacy and therapy control delivered easily and comfortably